『Community Health Media』のカバーアート

Community Health Media

Community Health Media

著者： Community Health Media
無料で聴く

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsCommunity Health Media 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

    Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC
    2026/07/21
    A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment.The conversation explores:Why DB09 may replace the CLEOPATRA standardThe significance of 40+ month median PFSComplete response rates and treatment durabilityManaging ILD, fatigue, nausea, and alopeciaMaintenance therapy strategiesPATINA and HER2CLIMB-05 insightsSequencing after T-DXd progressionWhy “saving your best drug for later” may no longer applyThis is a must-watch discussion on the evolving frontline landscape in HER2+ metastatic breast cancer.–Thanks for watching!Our podcasts are also available on:Spotify - https://spotf.fi/chm-podcastAmazon Music - https://amazn.so/chm-podcastApple Podcast - https://podcasts.apple.com/us/podcast...Castbox - https://castbox.fm/vh/6735434Goodpods - https://goodpods.com/profile/chm-111066iHeartRadio - https://iheart.com/podcast/291542082Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media
    続きを読む 一部表示
    55 分
  • Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC

    Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
    2026/07/07
    Can we improve outcomes by changing treatment before radiographic progression occurs?In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations.Topics discussed include:The clinical impact of the SERENA-6 trialUsing ctDNA to detect ESR1 mutations before disease progressionWhen and why to switch endocrine therapyCamizestrant and molecularly guided treatment strategiesIntegrating biomarker monitoring into routine clinical practicePatient communication, monitoring, and quality-of-life considerationsPractical challenges and implementation in the community settingFeaturing expert insights from Dr. Anne O'Dea and Dr. Mabel Mardones on one of the most important advances in precision oncology for HR-positive metastatic breast cancer.Watch the full conversation and subscribe for more expert discussions on the latest clinical evidence shaping cancer care.–Thanks for watching!Our podcasts are also available on:Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠
    続きを読む 一部表示
    32 分
  • Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

    Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09
    2026/06/26
    HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease?In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed:How DESTINY-Breast11 is changing neoadjuvant treatment strategiesDESTINY-Breast05 and the role of T-DXd for residual diseaseWhich patients should receive T-DXd versus T-DM1Managing ILD risk and monitoring requirementsTreatment decisions for patients who do not achieve pCRRechallenging T-DXd after recurrenceFirst-line metastatic HER2-positive breast cancer after DESTINY-Breast09Deep responses, complete responses, and long-term outcomesT-DXd versus THP in clinical practicePATINA, HER2CLIMB-05, and evolving maintenance strategiesCNS metastases and the role of HER2-targeted ADCsTreatment holidays, ctDNA monitoring, and personalized careAs T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape.Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media.–Thanks for watching!Our podcasts are also available on:Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠
    続きを読む 一部表示
    33 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません